{
    "clinical_study": {
        "@rank": "129632", 
        "acronym": "MIMIC", 
        "arm_group": [
            {
                "arm_group_label": "Maltodextrin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days"
            }, 
            {
                "arm_group_label": "Ispaghula", 
                "arm_group_type": "Active Comparator", 
                "description": "7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to test how well magnetic resonance imaging (MRI) can measure\n      whole gut transit time in people with constipation, and how readily it can detect a change\n      in transit time induced by taking a dietary supplement with laxative effects.The\n      investigators expect to demonstrate that ispaghula (psyllium) accelerates movement of matter\n      through the intestinal tract.\n\n      The investigators will also assess whether a change in gut bacteria and the chemicals that\n      they release can be detected."
        }, 
        "brief_title": "MRI and Microbiota Analysis in Constipation", 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets Rome III Criteria for diagnosis of Functional Constipation5 on questionnaire\n\n          -  At least one bowel motion per week while taking usual laxatives\n\n          -  Able to give informed consent\n\n          -  Aged 18 or older\n\n        Exclusion Criteria:\n\n          -  History declared by the candidate of other pre-existing gastrointestinal disorder,\n             including but not limited to:\n\n          -  Inflammatory Bowel Disease\n\n          -  Coeliac Disease\n\n          -  Pancreatitis\n\n          -  Gallstone disease (biliary colic, cholecystitis; asymptomatic presence of gallstones\n             permitted)\n\n          -  Diverticulitis (asymptomatic presence of diverticula permitted)\n\n          -  Cancer of the gastrointestinal tract\n\n          -  Irritable Bowel Syndrome\n\n          -  Any reported history of gastrointestinal resection (excluding appendicectomy or\n             cholecystectomy)\n\n          -  Presence of an intestinal stoma\n\n          -  Pregnancy declared by candidate (no formal testing)\n\n          -  Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of\n             metallic foreign body in eye(s) and penetrating eye injury\n\n          -  Reported alcohol intake of >28 units/ week with daily drinking\n\n          -  Unwilling to abstain from nicotine-containing products for the MRI study days (Visits\n             4 and 8)\n\n          -  Any use of a product containing ispaghula or psyllium in the 4 weeks prior to consent\n\n          -  Unable to avoid use of dihydrocodeine or morphine during the study\n\n          -  If taking other regular opiates such as codeine, fentanyl or Oxycodone, participants\n             should be able to maintain a stable dose throughout the study\n\n          -  Any reported history of hypersensitivity or significant adverse reaction to\n             ispaghula, maltodextrin or bisacodyl\n\n          -  Unable to stop drugs and other agents used primarily for their laxative effect,\n             during periods of screening, washout, baseline and treatment (maximum 15 days -\n             rescue medication will be provided).\n\n          -  Antibiotic or prescribed probiotic treatment in the past 4 weeks\n\n          -  Inability to lie flat or exceed scanner limits of weight <120kg\n\n          -  Poor understanding of English language\n\n          -  Participation in any medical trials for the past 3 months\n\n          -  Any condition where the candidate is likely to require a course of antibiotics in the\n             next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract\n             infection, lower limb ulceration\n\n          -  Judgement by the PI that the candidate who will be unable to comply with the full\n             study protocol e.g. Diabetes, severe COPD\n\n        During the screening 2 weeks off laxatives\n\n          -  No bowel motions recorded during screening period\n\n          -  \u22656 spontaneous bowel motions (SBMs - bowel motion without the use of rescue therapy\n             in the preceding 24 hours) per week\n\n          -  \u22653 complete spontaneous bowel motions (CSBMs - bowel motion with the feeling of\n             complete evacuation, without the use of rescue therapy in the preceding 24 hours) per\n             week\n\n          -  25% or more bowel motions having type 6 or 7 on the Bristol Stool Form Scale."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144376", 
            "org_study_id": "UON14011", 
            "secondary_id": "14GA006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ispaghula", 
                "intervention_name": "Ispaghula", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "psyllium"
            }, 
            {
                "arm_group_label": "Maltodextrin", 
                "intervention_name": "Maltodextrin", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Psyllium", 
                "Calcium polycarbophil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Constipation", 
            "psyllium", 
            "ispaghula", 
            "Magnetic Resonance Imaging", 
            "MRI", 
            "microbiota"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kathryn.murray@nottingham.ac.uk", 
                    "last_name": "Kathryn Murray, PhD", 
                    "phone": "+44 115 9515151"
                }, 
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG7 2UH"
                    }, 
                    "name": "University of Nottingham"
                }, 
                "investigator": {
                    "last_name": "Giles Major, BM BCh MRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "giles.major@nottingham.ac.uk", 
                    "last_name": "Giles Major, BM BCh MRCP", 
                    "phone": "+44 115 9515151"
                }, 
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG7 2UH"
                    }, 
                    "name": "Nottingham University Hospitals NHS Trust"
                }, 
                "investigator": {
                    "last_name": "Giles Major, BM Bh MRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Validation of Magnetic Resonance Imaging to Characterise Gastrointestinal Physiology, Gut Luminal Content and Its Interaction With Colonic Microbiota in Patients With Chronic Constipation", 
        "other_outcome": [
            {
                "description": "Area under the curve (mL.min) will be measured from hourly MRI scans by segmentation into ascending colon (AC), transverse colon (TC) and descending colon (DC)", 
                "measure": "Colonic volume", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Area under the curve (mL.min), measured  on hourly MRI scans by segmentation into AC, TC and DC", 
                "measure": "Colonic gas volume", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Area under the curve (mL.min) measured on hourly MRI scans", 
                "measure": "Gastric volume", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Measured at the umbilicus in cm, determined by MRI", 
                "measure": "Abdominal circumference", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Stool will be sampled during the baseline week and between days 3-7 of the intervention week during each treatment period", 
                "measure": "Change from baseline of stool water content percentage by mass", 
                "safety_issue": "No", 
                "time_frame": "after an average 5 days of intervention"
            }, 
            {
                "description": "Each treatment period includes 1 day washout, 7 days baseline, up to 7 (minimum 6) days intervention. Total = 15 days.\nStool frequency will be sampled on days 2-8 and 9-14, since participants may stop taking intervention before day 15.", 
                "measure": "Change from baseline in stool frequency", 
                "safety_issue": "No", 
                "time_frame": "during days 9-14 of treatment period"
            }, 
            {
                "description": "Each treatment period includes 1 day washout, 7 days baseline, up to 7 (minimum 6) days intervention. Total = 15 days.\nStool consistency will be sampled on days 2-8 and 9-14, since participants may stop taking intervention before day 15.", 
                "measure": "Change from baseline in stool consistency", 
                "safety_issue": "No", 
                "time_frame": "During days 9-14 of treatment period"
            }, 
            {
                "description": "Will be assessed for relative abundance, richness and diversity", 
                "measure": "Change from baseline in faecal microbiota", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline after an average 5 days of intervention"
            }, 
            {
                "description": "Stool samples collected during baseline week and after 3 or more days of intervention in each treatment period.", 
                "measure": "Change from baseline in faecal short-chain fatty acids", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline after an average 5 days of intervention"
            }, 
            {
                "description": "4 symptoms will be measured on 2 scales: a previously validated questionnaire on an ordinal scale (OS) of 0 (none), 1 (mild/ distinct but negligible), 2 (moderate/ annoying), 3 (severe/ disabling); and a Visual Analogue Scale (VAS) (0-100)\nSymptoms include abdominal pain, bloating, gas/flatulence, and diarrhoea. Clinically important symptoms will be defined as additive total score of 3 or greater on OS. VAS scores will be analysed alongside MRI data", 
                "measure": "Symptoms during study day", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }
        ], 
        "overall_contact": {
            "email": "giles.major@nottingham.ac.uk", 
            "last_name": "Giles Major, BM BCh MRCP", 
            "phone": "+44 115 9515151"
        }, 
        "overall_contact_backup": {
            "last_name": "Robin Spiller, MD FRCP", 
            "phone": "+44 115 9515151"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Robin Spiller, MSc MD FRCP", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Giles Major, BM BCh MRCP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Luca Marciani, MSc PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After 4 days of study product participants will ingest 5 transit mark capsules, the use of which has been shown to measure whole gut transit in a similar manner to more established techniques. They will continue to take study product before undergoing an MRI scan to assess capsule position", 
            "measure": "Weighted Average Position Score of transit marker capsules as determined by MRI", 
            "safety_issue": "No", 
            "time_frame": "24 hours after ingestion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144376"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "After 4 days of study product participants will ingest 5 transit mark capsules, the use of which has been shown to measure whole gut transit in a similar manner to more established techniques. They will continue to take study product before undergoing an MRI scan to assess capsule position", 
                "measure": "Weighted Average Position Score of 5 transit marker capsules, as determined by MRI", 
                "safety_issue": "No", 
                "time_frame": "48 hours after ingestion"
            }, 
            {
                "description": "Area under the curve (mL.min) will be calculated from hourly MRI scans", 
                "measure": "Small Bowel Water Content (SBWC) in millilitres(mL) measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "After 5 days of taking the study product participants will undergo an MRI scan while fasted.", 
                "measure": "Small Bowel Water Content (SBWC) in millilitres measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 60 minutes before test meal"
            }, 
            {
                "description": "After 5 days taking study product participants will undergo an MRI scan while fasted", 
                "measure": "Ascending Colon Water Content in millilitres measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 60 minutes before test meal"
            }, 
            {
                "description": "Area under the curve (mL.min) will be calculated from hourly MRI scans", 
                "measure": "Ascending Colon Water Content in millilitres measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Difference between measurement Meal -60 (fasting) and Meal +60", 
                "measure": "Change from baseline in Ascending Colon Water Content in millilitre measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "test meal -60, test meal +60"
            }, 
            {
                "description": "Difference between time points Meal2 -20 and Meal 2 +40", 
                "measure": "Change from before to after challenge meal in Ascending Colon Water Content before in millilitre measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "test meal +360 minutes, test meal + 420 minutes"
            }, 
            {
                "description": "Area under the curve of MRI parameter measured at hourly time points", 
                "measure": "Ascending Colon T1", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Area under the curve of MRI parameter measured at hourly time points", 
                "measure": "Descending Colon T1", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Area under the curve of MRI parameter measured at hourly time points", 
                "measure": "Ascending colon T2", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }, 
            {
                "description": "Area under the curve of MRI parameter measured at hourly time points", 
                "measure": "Descending Colon T2", 
                "safety_issue": "No", 
                "time_frame": "-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal"
            }
        ], 
        "source": "University of Nottingham", 
        "sponsors": {
            "collaborator": {
                "agency": "Ironwood Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Nottingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}